* Protagonist Therapeutics Inc reported a quarterly adjusted loss of 50 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -68 cents. The mean expectation of six analysts for the quarter was for a loss of 60 cents per share. Wall Street expected results to range from -81 cents to 5 cents per share.
* Revenue was $4.17 million; analysts expected $8.00 million.
* Protagonist Therapeutics Inc's reported EPS for the quarter was a loss of 50 cents.
* The company reported a quarterly loss of $30.62 million.
* Protagonist Therapeutics Inc shares had risen by 3.3% this quarter and gained 56.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 342% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $48.00 This summary was machine generated from LSEG data August 6 at 01:10 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.60 -0.50 Beat
Mar. 31 2024 1.19 3.26 Beat
Dec. 31 2023 -0.03 0.44 Beat
Sep. 30 2023 -0.69 -0.58 Beat
Comments